155 related articles for article (PubMed ID: 11427892)
1. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
Nardese V; Longhi R; Polo S; Sironi F; Arcelloni C; Paroni R; DeSantis C; Sarmientos P; Rizzi M; Bolognesi M; Pavone V; Lusso P
Nat Struct Biol; 2001 Jul; 8(7):611-5. PubMed ID: 11427892
[TBL] [Abstract][Full Text] [Related]
2. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
3. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
4. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
Owais M; Arya SK
J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
[TBL] [Abstract][Full Text] [Related]
6. Recognition of RANTES by extracellular parts of the CCR5 receptor.
Duma L; Häussinger D; Rogowski M; Lusso P; Grzesiek S
J Mol Biol; 2007 Jan; 365(4):1063-75. PubMed ID: 17101151
[TBL] [Abstract][Full Text] [Related]
7. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES.
Wilken J; Hoover D; Thompson DA; Barlow PN; McSparron H; Picard L; Wlodawer A; Lubkowski J; Kent SB
Chem Biol; 1999 Jan; 6(1):43-51. PubMed ID: 9889151
[TBL] [Abstract][Full Text] [Related]
8. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
9. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
10. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages.
Ylisastigui L; Vizzavona J; Drakopoulou E; Paindavoine P; Calvo CF; Parmentier M; Gluckman JC; Vita C; Benjouad A
AIDS; 1998 Jun; 12(9):977-84. PubMed ID: 9662193
[TBL] [Abstract][Full Text] [Related]
11. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.
Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z
Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591
[TBL] [Abstract][Full Text] [Related]
12. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
13. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
15. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
[TBL] [Abstract][Full Text] [Related]
16. Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES.
Nisius L; Rogowski M; Vangelista L; Grzesiek S
Protein Expr Purif; 2008 Oct; 61(2):155-62. PubMed ID: 18588983
[TBL] [Abstract][Full Text] [Related]
17. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
[TBL] [Abstract][Full Text] [Related]
20. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
